Edition:
India

Selecta Biosciences Inc (SELB.OQ)

SELB.OQ on NASDAQ Stock Exchange Global Market

1.72USD
18 Jul 2019
Change (% chg)

-- (--)
Prev Close
$1.72
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
135,286
52-wk High
$16.47
52-wk Low
$1.41

Latest Key Developments (Source: Significant Developments)

Selecta Biosciences Appoints Carsten Brunn, Ph.D. As President And CEO
Thursday, 27 Sep 2018 

Sept 27 (Reuters) - Selecta Biosciences Inc ::SELECTA BIOSCIENCES APPOINTS CARSTEN BRUNN, PH.D. AS PRESIDENT AND CHIEF EXECUTIVE OFFICER.SELECTA BIOSCIENCES INC - CARSTEN BRUNN, HAS BEEN APPOINTED CHIEF EXECUTIVE OFFICER OF SELECTA BIOSCIENCES, EFFECTIVE DECEMBER 1, 2018.SELECTA BIOSCIENCES INC - CARSTEN BRUNN WILL ALSO SERVE ON COMPANY'S BOARD OF DIRECTORS.SELECTA BIOSCIENCES - CURRENT CEO WERNER CAUTREELS WILL CONTINUE TO LEAD COMPANY UNTIL DECEMBER & WILL REMAIN MEMBER OF BOARD THROUGH DECEMBER 31.SELECTA BIOSCIENCES INC - CAUTREELS IS EXPECTED TO SERVE AS AN ADVISOR TO COMPANY FOLLOWING HIS RETIREMENT.  Full Article

Selecta Biosciences Announces Q2 Loss Per Share $0.84
Wednesday, 8 Aug 2018 

Aug 8 (Reuters) - Selecta Biosciences Inc ::SELECTA BIOSCIENCES ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $0.84.Q2 EARNINGS PER SHARE VIEW $-0.68 -- THOMSON REUTERS I/B/E/S.  Full Article

Selecta Biosciences Says Expects To Report Initial Results For Phase 2 Clinical Trial Of SEL-212 In Chronic Severe Gout In April 2018
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Selecta Biosciences Inc ::SELECTA BIOSCIENCES SAYS EXPECTS TO REPORT INITIAL RESULTS FOR PHASE 2 CLINICAL TRIAL OF SEL-212 IN CHRONIC SEVERE GOUT IN APRIL 2018 - SEC FILING.SELECTA BIOSCIENCES - EXPECTS TO SUBMIT INVESTIGATIONAL NEW DRUG APPLICATION FOR SEL-302 IN METHYLMALONIC ACIDEMIA IN 2019.  Full Article

Selecta Biosciences Announces FDA Acceptance Of Investigational New Drug Application For Lmb-100 And Svp-Rapamycin Combination Therapy
Tuesday, 2 Jan 2018 

Jan 2 (Reuters) - Selecta Biosciences Inc ::SELECTA BIOSCIENCES ANNOUNCES FDA ACCEPTANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR LMB-100 AND SVP-RAPAMYCIN COMBINATION THERAPY.SELECTA BIOSCIENCES INC - ENROLLMENT OF UP TO 18 PATIENTS IS EXPECTED TO BEGIN AT NCI DURING Q1 OF 2018.  Full Article

Selecta Biosciences Says CEO Werner Cautreels Plans Retirement at 2018 End
Tuesday, 2 Jan 2018 

Jan 2 (Reuters) - Selecta Biosciences Inc ::SELECTA BIOSCIENCES ANNOUNCES CEO’S INTENT TO RETIRE AND TRANSITION PLAN.SELECTA BIOSCIENCES INC - CEO WERNER CAUTREELS PLANS RETIREMENT AT END OF 2018.SELECTA BIOSCIENCES INC - OMID FAROKHZAD APPOINTED CHAIRMAN OF BOARD.SELECTA BIOSCIENCES INC - EXPECTS CAUTREELS TO REMAIN A MEMBER OF BOARD FOLLOWING HIS RETIREMENT.  Full Article

Selecta Biosciences announces Q3 loss per share $0.66
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Selecta Biosciences Inc :Selecta Biosciences announces third quarter 2017 financial results and provides corporate update.Q3 revenue $100,000 versus $1.0 million.Q3 revenue view $383,000 -- Thomson Reuters I/B/E/S.Q3 loss per share $0.66.Selecta -‍ Cash, cash equivalents, short-term deposits, investments & restricted cash sufficient to fund expenditure requirements into mid-2019​.  Full Article

Selecta Biosciences names John Leaman chief financial officer
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Selecta Biosciences Inc :Selecta Biosciences announces important additions to senior leadership team.Selecta Biosciences Inc - ‍Appointment of John Leaman as company's new chief financial officer and head of corporate strategy​.  Full Article